Abstract Purpose: Mesothelin is overexpressed in many pancreatic and ovarian cancers, mesotheliomas, and other tumor types. Clinical trials are ongoing using immunotoxins to target mesothelin, and patients immunized with allogeneic pancreatic tumor cell lines have shown immune responses to previously defined mesothelin epitopes.The purpose of this study was to define novel mesothelin CTL epitopes and, more importantly, agonist epitopes that would more efficiently activate human Tcells to more efficiently lyse human tumors. Experimental Design and Results: Two novel mesothelin HLA-A2 epitopes were defined. T-cell lines generated from one of these epitopes were shown to lyse pancreatic and ovarian tumor cells. Several agonist epitopes were defined and were shown to (a) have higher affinity and avidity for HLA-A2, (b) activate mesothelin-specific T cells from normal individuals or cancer patients to a greater degree than the native epitope in terms of induction of higher levels of IFN-g and the chemokine lymphotactin, and (c) lyse several mesothelin-expressing tumor types in a MHCrestricted manner more effectively thanTcells generated using the native peptide. External beam radiation of tumor cells at nontoxic levels was shown to enhance the expression of mesothelin and other accessory molecules, resulting in a modest but statistically significant increase in tumor cell lysis by mesothelin-specificTcells. Conclusions: The identification of novel CTL agonist epitopes supports and extends observations that mesothelin is a potential target for immunotherapy of pancreatic and ovarian cancers, as well as mesotheliomas.
Mesothelin, a glycosylphosphatidylinositol-linked glycoprotein, is a differentiation antigen of mesothelial cells. The cDNA encodes a M r 69,000 precursor protein, which is proteolytically processed into two components. One component, corresponding to the COOH-terminal portion of the precursor, is a membrane-bound M r 40,000 protein known as mesothelin. The other component is a M r 30,000 protein, corresponding to the NH 2 -terminal -secreted protein megakaryocyte potentiating factor (1 -3) . In humans, mesothelin is expressed in normal mesothelium and certain epithelial cells of the tonsil, trachea, and fallopian tube (4) . Mesothelin is overexpressed in a vast majority of ductal pancreatic adenocarcinomas; mesotheliomas; and adenocarcinomas of the ovary, lung, and stomach (5 -14) . Mesothelin has also been reported in squamous cell carcinomas of the esophagus, lung, and cervix (15) .
The presence of mesothelin in many cancer cells makes it a potential target for cancer therapies. A monoclonal antibody, K1, which recognizes mesothelin, has been developed and used in preclinical studies (4, 16) . Later, a high-affinity antimesothelin antibody was isolated by phage display (17) and after affinity improvement (18) was converted to a disulfide-linked Fv and fused to a 38 kDa portion of Pseudomonas exotoxin A to make immunotoxin SS1(dsFv)-PE38 (3). SS1(dsFv)-PE38 selectively inhibited experimental human lung cancer metastases in nude mice as well as showed antitumor activity against tumor cells obtained from patients with ovarian cancer and peritoneal mesotheliomas (19 -21) . Immunotoxins directed against mesothelin are currently in clinical trials (22, 23) .
Mesothelin is also a potential target for T-cell direct immunity. Potential CTL epitopes of mesothelin specific for HLA-A2, HLA-A3, and HLA-A24 have recently been reported. CD8 + T-cell responses to these HLA-A2, HLA-A3, and HLA-A24 epitopes were detected in patients vaccinated with granulocyte macrophage-colony stimulating factor -transduced pancreatic cancer cell lines (24) . These studies provided evidence of crosspriming postvaccination, which was directed against mesothelin-specific epitopes (24) .
Several preclinical studies have shown that the modification of CTL epitopes to render them more immunogenic will result in enhanced antitumor responses. Recent clinical studies in melanoma and colorectal cancer have also shown that vaccination with such agonist epitopes can result in the generation of greater levels of T-cell responses in patients, which have correlated with clinical responses (25, 26) . It has also recently been shown that agonist epitopes have the ability to stimulate T cells to produce more lymphotactin. Lymphotactin is a member of the C-chemokine family cloned from activated pro-T cells (27, 28) . It is produced by activated CD4 + and CD8 + T cells, natural killer cells, intraepithelial gy T cells, and mast cells (29 -31) . Lymphotactin is a powerful chemoattractant for CD4 + and CD8 + T cells and a moderate chemoattractant for natural killer cells (28, 30) .
The study described here reports the identification and characterization of a novel mesothelin CTL epitope, and the generation of an enhancer agonist of this epitope. T-cell lines, generated from a pancreatic cancer patient with the agonist peptide, showed high levels of lysis of mesothelin-expressing tumor cells and enhanced IFN-g and lymphotactin production when target cells were pulsed with the agonist peptide versus the native peptide. The studies reported here also show that the use of nontoxic doses of external beam radiation of tumor cells will enhance the expression of mesothelin and other accessory molecules and render tumor cells more susceptible to mesothelin-specific T-cell killing. These studies thus provide the rationale for the potential utility of the novel mesothelin agonist epitope, alone or in concert with previously defined mesothelin epitopes, in peptide-and/or vector-mediated immunotherapy protocols for the treatment of mesothelinexpressing tumors.
Materials and Methods
Cell cultures. A human pancreatic adenocarcinoma cell line CFPAC-1 (HLA-A2 positive and mesothelin positive; ref. 32), a human colon carcinoma SW1463 (HLA-A2 positive, mesothelin negative), a human ovarian adenocarcinoma cell line OVCAR-3 (HLA-A2 positive, mesothelin positive), and a human pancreatic adenocarcinoma cell line AsPC-1 (HLA-A2 negative and mesothelin positive) were purchased from American Type Culture Collection (Manassas, VA). Three HLA-A2 -positive and mesothelin-positive peritoneal mesothelioma cell lines (YOU, ROB, and ORT), a human epidermoid carcinoma cell line A431 (HLA-A2 negative, mesothelin negative), and A431.H9 cell line were obtained from Dr. Raffit Hassan (National Cancer Institute, NIH, Bethesda, MD). A431 cells transfected with pMH107, pcDNA3.1(+) vector containing a full-length mesothelin cDNA are designated as A431.H9. A431.H9 is a stable transfected cell line (33) . The cultures were free of Mycoplasma and were maintained in complete medium [RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 100 units/ mL penicillin, and 100 Ag/mL streptomycin (Invitrogen Life Technologies)]. The C1R cell line is a human plasma leukemia cell line that does not express endogenous HLA-A or HLA-B antigens (34) . C1R-A2 cells are C1R cells that express a transfected genomic clone of HLA-A2.1 (35) . These cells were obtained from Dr. William E. Biddison (National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD). The 174CEM-T2 cell line (T2) transport deletion mutant (36) was provided by Dr. Peter Cresswell (Yale University School of Medicine, New Haven, CT). C1R-A2 cells and T2 cells were Mycoplasma-free and were maintained in RPMI 1640 complete medium and in Iscove's modified Dulbecco's complete medium (Invitrogen Life Technologies), respectively.
Peptides. The amino acid sequence of mesothelin was scanned for matches to consensus motifs for HLA-A2 -binding peptides. We used the computer algorithm from the BioInformatics and Molecule Analysis Section of NIH, developed by Parker et al. (37) , which ranks potential MHC-binding peptides according to the predictive one-half-time dissociation of peptide/MHC complexes. The HLA-A2 allele was chosen because it is the most commonly expressed class I allele. Nine-mer and 10-mer peptides were synthesized if they conformed to the respective consensus motif. A panel of 10-mer mesothelin peptides (Table 1) and analogues with one -, two -, or three -amino acid substitution of P-547-556 peptide and MUC-1 peptide (38) were made by American Peptide Company (Sunnyvale, CA) with purity >90%.
Flow cytometric analysis. Dual-color flow cytometric analysis was done on T-cell lines by using the following antibody combinations: anti -CD56-FITC/anti -CD8-PE, anti -CD8-FITC/anti -CD45RA-PE, anti -CD8-FITC/anti -CD27-PE, and anti -CD8-FITC/anti -CD28 PE. Antibodies were all purchased from BD Biosciences (San Jose, CA). Staining was conducted simultaneously for 1 hour at 4jC; cells were then washed thrice with cold Ca 2+ -and Mg
2+
-free PBS, resuspended in the same buffer, and immediately analyzed using a FACScan and the CELLQuest program (BD Biosciences). Data were gathered from 10,000 live cells, stored, and used to generate results.
The procedure for analysis of dendritic cells was similar to the one described above. The following antibody combinations were used: anti -MHC-class II-FITC/anti -CD80-PE, anti -CD58-FITC/anti -CD54-PE, anti -MHC class I-FITC/anti -MHC class II-PE, and antiIgG1-FITC/anti -IgG2a-PE (isotype controls). Antibodies to MHC class I and class II were purchased from Serotec (Oxford, United Kingdom); other antibodies were purchased from BD Biosciences. The method described by Fan et al. (19) using K1 antibody was used for the analysis of mesothelin expression on tumor cell lines. The cells were immediately analyzed using a Becton Dickinson FACScan equipped with a blue laser with an excitation of 15 mW at 488 nm. Data were gathered from 10,000 live cells, stored, and used to generate results.
Results were expressed in percentage of positive cells and mean fluorescence intensity. Mean fluorescence intensity was used to express the levels of fluorescence determined by measuring the average for all the cells in the gated fluorescence dot plot. The mean fluorescence intensity value was collected in log scale on the FACScan.
Peptide binding to HLA-A2. Binding of mesothelin peptides and the mesothelin analogues to HLA-A2 molecules was evaluated by the upregulation of HLA-A2 expression on T2 cells as shown by flow cytometry (39) .
Culture of dendritic cells from peripheral blood mononuclear cells. HLA-A2 normal donor peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood. PBMCs were separated using lymphocyte separation medium gradient (Organon Teknika, Durham, NC) as described previously (40) . Dendritic cells were prepared using a modification of the procedure described by Sallusto et al. (41) .
Generation of T-cell lines. Modification of the protocol described by Tsang et al. (42) was used to generate mesothelin-specific CTLs. To generate T-cell line T-1991-P-547, autologous dendritic cells were used as antigen-presenting cells (APC). Autologous nonadherent cells were then added to APCs at an effector-to-APC ratio of 10:1. Cultures were then incubated for 3 days at 37jC in a humidified atmosphere containing 5% CO 2 . The cultures were then supplemented with recombinant human interleukin 2 at a concentration of 20 units/mL for 7 days; the interleukin 2 -containing medium was replenished every 3 days. The 3-day incubation with peptide and 7-day interleukin 2 supplement constituted one in vitro stimulation (IVS) cycle. Primary cultures were restimulated with autologous dendritic cells as described above on day 11 to begin the next IVS cycle. Autologous dendritic cells were used as APCs for three IVS cycles. Irradiated (23,000 rad) autologous EBV-transformed B cells were used as APCs after the third IVS cycle. For the restimulation with EBV-transformed B cells, peptides at a concentration of 25 Ag/mL were used to pulse the autologous EBVtransformed B cells at an effector-to-APC ratio of 1:3 for restimulation. Cultures were then incubated for 3 days at 37jC in a humidified atmosphere containing 5% CO 2 . After removal of the peptidecontaining medium, the cultures were then supplemented with recombinant human interleukin 2 at a concentration of 20 units/mL for 7 days. T-cell lines from patient 55 (T-55-P-547, T-55-P-554L/556V, T-55-P-548M/554L/556V, T-55-P-548L/554L/556V) were generated by stimulation of PBMCs with autologous dendritic cells pulsed with the P-547 or the agonist peptides using the same stimulation protocol as described above. The markers used for the analysis and identification of dendritic cells were CD11c, MHC-class II, CD80, CD54, CD58, and CD83. CD3 was also used as a negative marker.
Cytotoxic assay. Cytotoxicity assays were used as described previously (42) .
Detection of cytokines. Supernatants of T cells exposed for 24 hours to peptide-pulsed autologous dendritic cells, in interleukin 2 -free medium at various peptide concentrations, were screened for secretion of IFN-g using an ELISA kit (BioSource International, Camarillo, CA) and lymphotactin using an ELISA assay (43) . The results were expressed in pg/mL.
Chemotaxis assay. Chemotactic responses were examined using the method described previously (44) . Briefly, blind Well Chambers (Neuroprobe, Gaithersburg, MD) with polyvinylpyrrolidone-free 5 Am pore size polycarbonate filters previously coated on one side with mouse Collagen IV (Trevigen, Gaithersburg, MD) were used. Supernatants from unstimulated T-55-P547 cells or T-55-P547 cells activated for 24 hours with 25 Ag/mL of either P547 or P547-2 peptide were added to the lower chambers, and healthy donor PBMCs (7.5 Â 10 4 cells, 75 AL in complete RPMI medium containing 1% human AB serum) were added to the upper chambers. As negative and positive controls, the lower chambers were loaded with medium alone or recombinant lymphotactin (50 ng/mL in complete RPMI medium containing 1% human AB serum), respectively. After incubation for 4 hours at 37jC, filters were removed from the chambers, fixed, and stained with Diff-Quik stain (Dade Behring, Inc., Newark, DE). Blocking assay was done using antilymphotactin antibody (R&D Systems, Inc., Minneapolis, MN). The number of cells associated with the lower side of the membranes was evaluated by direct counting of at least six Â40 objective fields for the standard samples or at least nine Â40 objective fields for the experimental samples.
Irradiation of tumor cells. Human tumor cell lines CFPAC-1, OVCAR-3, and AsPC-1 were irradiated as previously described (45, 46). Tumor cells were harvested in log-growth phase and were placed on ice and irradiated at 10 and 20 Gy by a Cesium-137 source (Gammacell-1000; AECL/Nordion, Kanata, Ontario, Canada) at a dose rate of 0.74 Gy/min. Control samples were also placed on ice but not irradiated. Irradiated and nonirradiated cells were then washed in fresh media and seeded in 75 cm 2 cell culture flasks. Cells were harvested for surface marker determination after 72 hours in culture by flow cytometry.
Vaccinia virus infection of epidermoid carcinoma cells. A recombinant vaccinia vector encoding HLA-A2.1 was used for the infection of A431 and A431.H9 cells. This recombinant virus was constructed by the insertion of the HLA-A2.1 gene into the BamHI J region of the genome of the Wyeth strain of vaccinia virus as described (47) . The gene is under control of the vaccinia 40k promoter (48) . Target cells at a concentration of 1 Â 10 7 /mL in complete RPMI 1640 supplemented with 0.1% bovine serum albumin were incubated with equal volume of vaccinia virus (10 8 plaque-forming units/mL) in the same medium at 37jC for 1 hour. The cells were then adjusted to a concentration of 5 Â 10 5 /mL in complete medium and incubated for 3 hours at 37jC. Statistical analysis. Statistical analysis of differences between means was done using a two-tailed paired t test (StatView statistical software, Abacus Concepts, Berkeley, CA).
Results
The primary amino acid sequence of human mesothelin was analyzed for consensus motifs for novel HLA-A2 -binding peptides. One 10-mer peptide and one 9-mer peptide were identified, subsequently synthesized, and investigated for binding to the HLA-A2 molecule in a T2 cell -binding assay. The amino acid sequences and the positions of these peptides are shown in Table 1 . The MUC-1 peptide and a carcinoembryonic antigen HLA-A3 -binding peptide (CAP-7) were used as positive and negative controls, respectively. Two of the peptides (P21-29 and P547-556) were shown to have positive binding in the T2 assay. Experiments were then conducted to compare the ability of the P21-29 and P547-556 peptides to bind HLA-A2 at various peptide concentrations. As seen in Fig. 1 , the P547-556 peptide bound to HLA-A2 at higher levels than did the P21-29 peptide at concentrations of 50, 25, 12.5, and 6.25 Ag/mL. The P547-556 peptide (designated as P547) was thus chosen for further study. Studies were then initiated to determine whether mesothelinspecific T-cell lines could be established from PBMCs from an apparently healthy donor. Autologous dendritic cells were used as APCs. The specificity of the mesothelin-specific T cells generated (designated T-1991-P547) was analyzed after IVS cycle 3 (see Materials and Methods) for the ability to release IFN-g and the chemokine lymphotactin after stimulation with autologous dendritic cells pulsed with the P547 peptide. When T-1991-P547 cells were stimulated with autologous dendritic cells pulsed with P547 peptide, the T cells produced 391 pg/mL IFN-g and 78 pg/mL lymphotactin, whereas the use of autologous dendritic cells pulsed with control CAP1-6D peptide or dendritic cells alone did not result in any IFN-g and lymphotactin production (i.e., <16 pg/mL). As determined by flow cytometric analysis, the T-1991-P547 cell line was 98.7% CD8 positive, 62.2% CD45RA positive, 1.1% CD28 positive, and 0.5% CD27 positive. The T-1991-P547 cell line was then analyzed for the ability to lyse mesothelin -positive and HLA-A2 -positive human tumor cell lines. AsPC-1 (HLA-A2 -negative and mesothelin-positive pancreatic cancer cell line) was used as a negative control. The expression of HLA-A2 and mesothelin on CFPAC-1, OVCAR-3, AsPC-1, SW1463, and C1R-A2 cell lines was analyzed by flow cytometry. As shown in Table 2 Analysis of the primary and secondary HLA-A2 -binding anchor amino acid residues at positions 1, 2, 8, and 10 of the P547 peptide revealed that modification of amino acids at these positions could potentially enhance the binding ability of the peptide to the HLA-A2 molecule. For this reason, eight different analogues of P547 peptide were synthesized, as shown in Table 1 , and were investigated for their binding ability to T2 cells along with the native P547 peptide. The carcinoembryonic antigen peptide CAP-7, which has previously been shown not to bind to T2 (42) , was used as a negative control. As shown in Table 1 , three of the eight analogues bound to HLA-A2 at higher levels than the native peptide. They were designated P547-2, P547-3, and P547-4. Experiments were then conducted to compare the ability of these three analogues to bind HLA-A2 at various concentrations. As shown in Fig. 2A , all bound to HLA-A2 at higher levels than did the native P547 peptide at all concentrations. These results indicated that these three analogues with modification in the primary anchor position 2 (position 548 of the mesothelin peptide) and position 10 (position 556 of the mesothelin peptide) as well as the secondary position 8 (position 554 of the mesothelin peptide) were potential agonists of peptide P547.
We then examined the stability of the peptide-MHC complex for P547 (native), and P547-2, P547-3, and P547-4 agonist peptides. The peptides were incubated with T2 cells overnight, and the unbound peptides were washed off and the cells were then incubated with Brefeldin A to block delivery of new class I molecules to the cell surface. Cells were analyzed for the presence of peptide -HLA-A2 complexes at various time points. In release assay was done. Results are expressed in percentage-specific lysis at effector-to-target ratio of 20:1.
*Statistical significance (P < 0.01, two tailed t test) when comparing lysis of CFPAC-1 cells versus AsPC-1 cells and OVCAR-3 versus AsPC-1 by T-1991-P547 cells.
As shown in Fig. 2B , all three HLA-A2 agonist complexes were more stable than the P547-HLA-A2 complex over the 8-hour observation period, with P547-4 slightly more stable than the P547-2 and P547-3 complexes over the same period of time. These data indicated that both the binding to the MHC molecule and the stability of the peptide-MHC complex were greater for the P547-2, P547-3, and P547-4 agonist peptides than the native P547 peptide.
Studies were then undertaken to compare the ability of the P547-2, P547-3, and P547-4 agonist peptides to activate the T-1991-P547 cells, which were generated with the native peptide. As seen in Table 3 , pulsing of APCs with P547-2 peptide led to greater levels of both IFN-g and lymphotactin production by T-1991-P547 cells compared with P547-3, P547-4, or the native P547 peptide. Studies were then conducted to compare the ability of the agonist peptides P-547-2, P547-3, P547-4, and the native P574 peptide at various peptide concentrations to activate T-1991-P547 cells in the production of lymphotactin. As shown in Fig. 3 , at concentrations of 3.13 Ag/mL and higher, the pulsing of APCs with P547-2 led to the highest level of lymphotactin production by the T-1991-P547 cell line. Fig. 2 . Binding of a native mesothelin peptide and its agonist peptides to HLA-A2. Peptides were analyzed for binding toT2 cell line as described in Materials and Methods. A, peptides were used at concentrations of 0 to 50 Ag/mL. P547 peptide (n), P547-2 (.), P547-3 (o), and P547-4 (4), positive control (MUC-1peptide; +) and negative control (HLA-A3^binding peptide; Â). Results are expressed in mean fluorescence intensity. B, comparison of the stability of HLA-A2 peptide complexes of mesothelin native and agonist peptides. T2 cells were incubated overnight with P547 (n), P547-2 (.), P547-3 (o), and P547-4 (4) peptides at a concentration of 25 Ag/mL and then were washed free of unbound peptide and incubated with Brefeldin A to block delivery of new class I molecules to the cell surface. At the indicated times, cells were stained for the presence of surface peptide^HLA-A2 complexes. Points, relative percentage of binding compared with 100% at time 0. The T-1991-P547 cell line was derived from an apparently healthy individual using the native P547 peptide. Studies were then conducted to determine whether additional T-cell lines could be generated from a patient with pancreatic cancer (patient 55) using the native or the three agonist peptides. Four mesothelin-specific T-cell lines were subsequently established and were designated T-55-P547, T-55-P547-2, T-55-P547-3, and T-55-P547-4. The T-cell lines were generated by stimulation of PBMCs from patient 55 using autologous dendritic cells. The ability of these T-cell lines to lyse mesothelin-positive and HLA-A2 -positive tumor cells was then investigated. As can be seen in Fig. 4 , all four T-cell lines were able to lyse the mesothelin-positive and HLA-A2 -positive CFPAC-1 cells and OVCAR-3 cells but showed no lysis against AsPC-1 (mesothelin positive, HLA-A2 negative) and SW1463 (mesothelin negative, HLA-A2 positive) cells. These results show the HLA-A2 and mesothelin specificity of the lysis. Furthermore, T-55-P547-2 cells, derived using P547-2 agonist peptide, showed greater lysis of tumor cells than the T cells derived using the native P-547, or the agonist P547-3 and P547-4 peptides. This was seen at three different effector-totarget ratios.
Experiments were then conducted to evaluate the ability of T-55-P547-2, T-55-P547-3, and T-55-P547-4 cells to produce lymphotactin when stimulated with the corresponding peptide. As shown in Table 4 , a higher level of lymphotactin production was observed when T-55-P547-2 cells were stimulated with the agonist P547-2 peptide compared with T-55-P547-3, T-55-P547-4, and T-55-P547 when stimulated with the corresponding peptide. Lymphotactin has been reported to enhance chemotaxis responses of various immune cells. A chemotaxis assay was thus done (see Materials and Methods) to confirm the functional activity of the lymphotactin in the supernatants of the mesothelin-specific T-cell line stimulated with APCs pulsed with the P547-2 agonist peptide. T-55-P547 cells were used in this study. As seen in Fig. 5A , supernatants from T-55-P547 cells stimulated with P547-2 peptide clearly enhanced migration of PBMCs over the responses to the supernatants from the native P547 peptide and the no peptide control. Purified recombinant human lymphotactin was also used as a positive control in the assay. To ascertain that the observed Fig. 4 . Ability of the mesothelin-specificT-cell lines established for a pancreatic cancer patient (patient 55) to lyse tumor cells expressing native mesothelin. T-55-P547 (derived from the native peptide;
),T-55-P547-2 (derived from the agonist peptide P547-2;
), T-55-P547-3 (derived from the agonist peptide P547-3;
), and T-55-P547-4 (derived from the agonist peptide P547-4;
). Effector-to-target ratio = 50:1, 25:1, and 12.5:1in a 16-hour 111 In release assay (see Materials and Methods). Bars, SD. Table 4 . Production of lymphotactin by T-cell lines generated from a pancreatic cancer patient (patient 55) stimulated with P547 and the agonist peptides . These T-cell lines were established by stimulation with P547-pulsed autologous dendritic cells (T-55-P547), P547-2^pulsed autologous dendritic cells (T-55-P547-2), P547-3^pulsed autologous dendritic cells (T-55-P547-3), or P-547-4^pulsed autologous dendritic cells (T-55-P547-4). For lymphotactin production, T-cell lines were stimulated with the corresponding peptide at a concentration of 25 Ag/mL and an effectorto-APC ratio of 10:1. CAP1-6D peptide was used as a negative control. Twenty-four-hour culture supernatants were collected and screened for the secretion of lymphotactin. chemotactin responses were due to the presence of lymphotactin, a chemotaxis assay was done with and without antilymphotactin antibody. As seen in Fig. 5B , the addition of antilymphotactin antibody inhibited the migration of PBMCs induced by the purified recombinant lymphotactin as well as the migration of PBMCs induced by the supernatants from T-55-P547 cells stimulated with APCs pulsed with the agonist peptide P547-2.
To further characterize the P547-2 peptide, an additional T-cell line was established from a colon carcinoma patient (patient 35) using P547-2 agonist peptide-pulsed autologous dendritic cells. This T-cell line was designated T-35-P547-2 and was 97.4% CD8 positive, <1% CD56 positive, 33.1% CD45RA positive, and 29.0% CD27 positive. The T-35-P547-2 cell line was shown to produce IFN-g (100 pg/mL) and lymphotactin (459 pg/mL) when stimulated with autologous dendritic cells pulsed with P547-2 agonist peptide. As seen in Table 5 , the T-35-P547-2 cell line also showed lysis of the mesothelin-positive and HLA-A2 -positive CFPAC-1 cells and OVCAR-3 cells at various effector-to-target ratios but showed no lysis of the mesothelin-positive and HLA-A2 -negative AsPC-1 cell line. In addition, the T-35-P547-2 cell line also lysed HLA-A2 -positive, mesothelin-positive mesothelioma cell lines YOU, ROB, and ORT, as shown in Table 5 . To confirm our hypothesis that tumor cells endogenously process mesothelin to present mesothelin peptide in the context of MHC for T-cell -mediated lysis, CFPAC-1 cells were used as target in a cold target inhibition assay. As shown in Table 6 , the addition of peptide-pulsed unlabeled T2 cells decreased the CTL activity of T-35-P547-2 cells against labeled CFPAC-1 cells. The cytotoxic activity of T-35-P547 cells against CFPAC-1 cells was shown to be HLA-A2 restricted as indicated by the inhibition of lysis with anti -HLA-A2 antibody but not with control antibody (Table 6 ). To further show that target cells can endogenously process the entire mesothelin molecule in a manner so as to bind HLA-A2 molecules for presentation at the cell surface, A431 cells were transfected with the entire human mesothelin gene (see Materials and Methods) and used as target cells in a T-cell cytotoxic assay. As seen in Table 7 , the mesothelin-transfected A431 cells designated as A431.H9 cells express mesothelin. A431.H9 cells were susceptible to lysis with T-35-P547-2 cells when transfected with rV-HLA-A2 recombinant expressing HLA-A2. These studies further show the endogenous process of mesothelin in A431.H9 cells and the HLA-A2 -restricted nature of the mesothelin-specific lysis of T-35-P547-2 cells.
It has been previously shown that sublethal irradiation of tumor cells can modulate their phenotype to render them more susceptible to T-cell -mediated killing (45, 46). We investigated whether sublethal doses of radiation would alter the expression of surface markers in CFPAC-1, OVCAR-3, and AsPC-1 cell lines. Tumor cells were subjected to 0 or 10 Gy radiation, and cell surface expression of mesothelin, HLA-A2, and intercellular adhesion molecule (ICAM)-1 was analyzed by flow cytometry after 72 hours. No significant increase in cell death was observed with 10 and 20 Gy radiation. As seen in Fig. 6A , slight or no increases in the percentage of cells expressing mesothelin, HLA-A2, and ICAM-1 were detected in the CFPAC-1 cell line at 10 Gy radiation compared with no radiation. This is due to the fact that the CFPAC-1 cell line has a high level of expression of these three molecules. The mean fluorescence intensity of ICAM-1, mesothelin, and HLA-A2, however, did increase (Fig. 6A) . As shown in Fig. 6B , increases in the percentage of mesothelin-expressing cells and ICAM-1 -expressing cells were observed in the OVCAR-3 cell line after irradiation at 10 Gy. No significant increase in the percentage of cells expressing these three markers was observed on AsPC-1 cells after irradiation at 10 Gy. The mean fluorescence intensity of expression of mesothelin, however, did increase after irradiation (Fig. 6C) . The functional significance of phenotypic changes of CFPAC-1 and OVCAR-3 cells after irradiation on the susceptibility to be lysed by mesothelin-specific T cells was investigated. The CFPAC-1 and OVCAR-3 cell lines both showed a significant (P < 0.01) increase in lysis by T-1991-P547, a mesothelin-specific T-cell line after 10 Gy of irradiation compared with the nonirradiated CFPAC-1 and OVCAR-3 cells (Fig. 7A and B) . The AsPC-1 cell line, a HLA-A2 -negative cell line not lysed by T-1991-P547, was used as a negative control (Fig. 7C) . 
Discussion
Mesothelin has previously been shown to be a potential target for both antibody-and vaccine-mediated immunotherapy. Preclinical studies using antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) showed the antitumor activity against mesothelin-expressing tumors (20, 21) . Two phase 1 clinical trials using SS1P are currently ongoing (22, 23) . Mesothelinderived HLA-A2 -, HLA-A3 -, and HLA-A24 -restricted CTL 9-mer epitopes have been previously reported (24) . These peptides were used for the detection of mesothelin-specific CD8 + T-cell immune responses in pancreatic cancer patients vaccinated with granulocyte macrophage-colony stimulating factor -transduced pancreatic cancer cells. The two HLA-A2 -binding peptides used in that study were mesothelin peptides 20 to 28 (SLLFLLFSL) and 530 to 538 (VLPLTVAEV; ref. 24 ). The results from that clinical trial provide evidence that CD8 + T-cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site. In the studies reported here, we have modified the primary anchor residues of a novel mesothelin peptide to augment the binding affinity of the peptide to the MHC molecule. Eight analogues were synthesized and analyzed; one of them, designated P547-2, was shown to be superior to the native epitope in terms of affinity of Table 6 . Cytotoxicity of a mesothelin-specific T-cell line (T-35-P547-2) against target cells with endogenous mesothelin expression and inhibition of lysis by anti-HLA-A2 antibody In release assay was done. Results are expressed in percentage specific lysis at an effector-to-target ratio of 20:1. cFor the cold target inhibition experiment, labeled CFPAC-1 cells and unlabeledT2 cells were used at a ratio of1:10.T2 cells were incubated with or without P547-2 peptide (25 Ag/mL) in serum-free medium for 24 hours at 37jC before their addition into the assay.
b Statistically significant difference (P < 0.01, two-tailed t test) for comparison with CFPAC-1cells and T2 cells not pulsed with peptide.
x For the anti^HLA-A2 antibody inhibition experiment, labeled CFPAC-1cells were incubated for 1hour in the presence of medium containing either 10 Ag/ mL of control antibody (UPC-10) or anti^HLA-A2 antibody (10 Ag/mL and 50 Ag/mL). Cells were then used as target in 16-hour cytotoxic assays. T-cell lines derived from the native or the agonist mesothelin epitope were shown to lyse mesothelin-positive and HLA-A2 -positive pancreatic cancer, ovarian cancer, and mesothelioma cell lines as well as mesothelin gene -transfected epidermoid carcinoma cells in an MHC-restricted manner. Moreover, such T-cell lines could be derived from a pancreatic cancer patient, a colon cancer patient, and a normal donor.
Preclinical and clinical studies have indicated that lymphotactin may be an important chemokine in attracting effector cells and thus enhancing immune responses. The results reported here show both enhanced synthesis of lymphotactin and enhanced biological activity of lymphotactin as a consequence of stimulation of effector T cells with the agonist mesothelin peptide.
Previous studies have shown that when murine and human tumor cells are exposed to sublethal irradiation, their phenotype can be altered to make them more susceptible to T-cell -mediated killing. This has been shown to be due to upregulation of either tumor antigen, MHC class I, or accessory molecules such as Fas or ICAM-1, or combinations of the above. The results reported here show that nonlethal irradiation of both a pancreatic and ovarian cancer cell line led to the upregulation of mesothelin, ICAM-1, and MHC class I, which subsequently rendered them more susceptible to lysis by a mesothelin-specific T-cell line.
The studies reported here thus extend previous observations on the suitability of mesothelin as a potential target for immunotherapy of a range of human tumors.
